1. Integrated Metabolomics and Transcriptomics Analysis of Anacardic Acid Inhibition of Breast Cancer Cell Viability.
- Author
-
Piell KM, Poulton CC, Stanley CG, Schultz DJ, and Klinge CM
- Subjects
- Humans, Female, Transcriptome drug effects, Cell Line, Tumor, Metabolome drug effects, Breast Neoplasms metabolism, Breast Neoplasms genetics, Breast Neoplasms drug therapy, Breast Neoplasms pathology, MCF-7 Cells, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic drug effects, Triple Negative Breast Neoplasms metabolism, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms pathology, Signal Transduction drug effects, Anacardic Acids pharmacology, Metabolomics methods, Cell Survival drug effects
- Abstract
Anacardic acid (AnAc) inhibits the growth of estrogen receptor α (ERα)-positive MCF-7 breast cancer (BC) cells and MDA-MB-231 triple-negative BC (TNBC) cells, without affecting primary breast epithelial cells. RNA sequencing (seq) and network analysis of AnAc-treated MCF-7 and MDA-MB-231 cells suggested that AnAc inhibited lipid biosynthesis and increased endoplasmic reticulum stress. To investigate the impact of AnAc on cellular metabolism, a comprehensive untargeted metabolomics analysis was performed in five independent replicates of control versus AnAc-treated MCF-7 and MDA-MB-231 cells and additional TNBC cell lines: MDA-MB-468, BT-20, and HCC1806. An analysis of the global metabolome identified key metabolic differences between control and AnAc-treated within each BC cell line and between MCF-7 and the TNBC cell lines as well as metabolic diversity among the four TNBC cell lines, reflecting TNBC heterogeneity. AnAc-regulated metabolites were involved in alanine, aspartate, glutamate, and glutathione metabolism; the pentose phosphate pathway; and the citric acid cycle. Integration of the transcriptome and metabolome data for MCF-7 and MDA-MB-231 identified Signal transduction: mTORC1 downstream signaling in both cell lines and additional cell-specific pathways. Together, these data suggest that AnAc treatment differentially alters multiple pools of cellular building blocks, nutrients, and transcripts resulting in reduced BC cell viability.
- Published
- 2024
- Full Text
- View/download PDF